Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 258Carcinoma, Non-Small-Cell Lung 226Carcinoma, Renal Cell 142Neoplasm Metastasis 97Neoplasms 92Squamous Cell Carcinoma of Head and Neck 84Carcinoma, Hepatocellular 84Colorectal Neoplasms 80Lung Neoplasms 73Stomach Neoplasms 56Pancreatic Neoplasms 56Carcinoma, Transitional Cell 49Hodgkin Disease 47Urinary Bladder Neoplasms 42Breast Neoplasms 40Ovarian Neoplasms 37Head and Neck Neoplasms 37Triple Negative Breast Neoplasms 34Small Cell Lung Carcinoma 33Sarcoma 32Glioblastoma 32Brain Neoplasms 32Prostatic Neoplasms 31Recurrence 27Kidney Neoplasms 27Multiple Myeloma 25Uveal Melanoma 23Esophageal Neoplasms 23Uterine Cervical Neoplasms 22Skin Neoplasms 22

Interventions

Gemcitabine 4lenvatinib 3durvalumab 3Cisplatin 3tislelizumab 2sintilimab 2pembrolizumab 2toripalimab 1titanium silicide 1theasinensin A 1surufatinib 1sitravatinib 1regorafenib 1S 1 (combination) 1Nivolumab 1Injections 1Folfox protocol 1Fluorouracil 1Cryosurgery 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Biliary Tract Cancer × Nivolumab × Clear all
NCT04172402 2025-07-22

NGS as the First-line Treatment in Advanced Biliary Tract Cancer

National Health Research Institutes, Taiwan

Phase 2 Completed
48 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡